If you use kratom regularly, recent headlines about 7-hydroxymitragynine (7-OH) may leave you wondering what is changing in New Jersey. Lawmakers are considering measures targeting 7-OH, while separate legislation would regulate certain kratom products rather than prohibit all botanical kratom.
That distinction matters because traditional kratom and concentrated 7-OH products are not pharmacologically equivalent. 7-OH is a potent opioid-receptor-active compound found naturally in kratom only at trace levels, while some commercial products concentrate or enrich it.
This article explains why 7-OH is considered controversial, why regulators are concerned, what is happening in New Jersey and nationally, and why people experiencing dependence should seek professional support rather than wait for the product to become unavailable.
7-OH Explained: What Is This Controversial Compound?
7-hydroxymitragynine, commonly called 7-OH, is one of the many alkaloids associated with the kratom plant (Mitragyna speciosa). It acts on the mu-opioid receptor, the same receptor system involved in the effects of conventional opioids. Research describes 7-OH as substantially more potent at this receptor than mitragynine, kratom’s primary alkaloid.
The key difference is concentration. Traditional kratom leaf contains only trace amounts of naturally occurring 7-OH, while newer commercial products may contain concentrated or semisynthetic 7-OH. These products are sold as tablets, gummies, shots, powders, strips, and capsules.
A 2026 analysis found evidence of semisynthetic 7-OH in more than 98% of products labeled as containing 7-OH and identified inconsistencies between labeled and measured amounts in some products. This helps explain why regulators increasingly distinguish botanical kratom from high-potency 7-OH products.
The Real Reason 7-OH Is Facing a Ban
The concern is not simply that 7-OH comes from kratom. Concentrated 7-OH can produce much stronger opioid-receptor activity than the trace amounts naturally present in traditional kratom.
The Food and Drug Administration describes concentrated 7-OH products as potent opioid products that have not been demonstrated to be safe or effective for any accepted medical use. These products have a high potential for abuse and may pose a serious health hazard.
Regulators are also concerned about concentrated and semisynthetic products being marketed as “kratom” and about inconsistencies between labeled and actual concentrations of 7-OH.
Together, potent opioid activity, concentrated formulations, uncertain product composition, and reports of harmful exposures have increased regulatory concern.
New Jersey’s Proposed 7-OH Rules Explained
New Jersey is considering several measures that would place tighter restrictions on 7-OH, but 7-OH is not currently banned statewide. The proposals take different approaches to 7-OH and kratom products.
Senate Bill 301 would classify 7-OH as a Schedule I controlled dangerous substance. The bill was reported favorably by the Senate Health, Human Services and Senior Citizens Committee on March 16, 2026.
Assembly Bill 1636 also proposes Schedule I substance classification while going further by restricting the sale, manufacture, and distribution of products made with or containing 7-OH. It would also establish recall procedures for products covered by the bill.
Meanwhile, Senate Bill 1384 takes a broader regulatory approach to kratom through a proposed New Jersey Kratom Consumer Protection Act. The bill would establish requirements for labeling, testing, age restrictions, and product composition, including prohibiting kratom products containing more than 2% 7-OH in the alkaloid fraction and products containing synthetic kratom alkaloids.
Because these measures are still proposals, it is more accurate to say that New Jersey is considering a 7-OH ban or tighter restrictions rather than saying a statewide ban is already in effect. The legislation also shows that the state’s approach is not simply a blanket ban on kratom, but an effort to distinguish between concentrated or synthetic 7-OH products and regulated botanical kratom products.
7-OH vs. Kratom: The Difference Matters
It is easy to use the words “kratom” and “7-OH” interchangeably, but doing so can obscure an important scientific distinction.
| Category | Traditional botanical kratom | Concentrated/enriched 7-OH |
| Source | Leaves of Mitragyna speciosa | Often concentrated or semisynthetic 7-OH |
| Main alkaloid | Mitragynine | 7-hydroxymitragynine |
| Natural 7-OH level | Trace amounts | May be substantially enriched |
| Opioid-receptor activity | Multiple alkaloids with complex effects | Potent activity at the mu-opioid receptor |
| Product forms | Leaf, powder, tea and extracts | Tablets, gummies, shots, strips, powders and other concentrated products |
| Regulatory focus | Varies by product and jurisdiction | Increasingly targeted by FDA, DEA and state lawmakers |
Traditional kratom itself also deserves careful, non-sensational discussion. Research on kratom is still developing, and its alkaloids have complex pharmacological effects.
The Hidden Risks of 7-OH You Should Know
Regular 7-OH use can lead to physical dependence, meaning withdrawal may occur when use is stopped. A 2026 case report documented acute opioid withdrawal after discontinuing high-dose concentrated 7-OH, including nausea, diarrhea, abdominal cramping, restlessness, chills or clamminess, and anxiety.
The FDA has also received reports of withdrawal symptoms including restlessness, body aches, fatigue, irritability, and cold sweats, along with other reported concerns such as anxiety, gastrointestinal symptoms, insomnia, and seizures.
Overdose and polysubstance use
The CDC analyzed 14,449 kratom-related poison-center exposure reports from 2015 through 2025. Reports increased from 258 in 2015 to 3,434 in 2025, an increase of approximately 1,200%.
Among 233 kratom-associated deaths, 184 (79%) involved multiple substances. Opioids, benzodiazepines, stimulants, and alcohol were among those reported alongside kratom.
The CDC cannot determine whether these exposures involved traditional kratom, concentrated extracts, or 7-OH specifically. The data therefore indicate a growing kratom-related threat to public safety signal rather than a 7-OH-specific death rate.
Why the FDA Is Sounding the Alarm on 7-OH
The FDA began publicly escalating its warnings about 7-OH in 2025. It issued warning letters to companies marketing concentrated 7-OH products and said that 7-OH is not a lawful dietary supplement ingredient or an FDA-approved drug.
In July 2025, the FDA recommended federal scheduling action for certain 7-OH products, specifically distinguishing concentrated 7-OH from natural kratom leaf products.
The FDA has continued enforcement activity. In December 2025, it announced the seizure of approximately 73,000 units of concentrated 7-OH products from three firms.
The federal picture developed further in 2026. The United States Drug Enforcement Administration (DEA) announced in July 2026 that it intends to begin a temporary scheduling process to place 7-OH and three related substances into Schedule I of the Controlled Substances Act for public health safety.
The proposed action focuses on synthesized and highly concentrated 7-OH products rather than botanical kratom products containing naturally occurring 7-OH below the specified threshold.
Could a 7-OH Ban Change What You Can Buy?
Potentially. If federal or state temporary scheduling order restrictions take effect, some 7-OH products could become unavailable. For someone physically dependent on 7-OH, sudden loss of access could also trigger withdrawal and create pressure to seek another substance.
This does not mean a 7-OH ban will inevitably lead people to heroin or fentanyl. There is no evidence establishing that outcome. The concern is that some dependent individuals may seek another opioid or intoxicating substance to avoid withdrawal, making supply disruption an issue worth monitoring.
What the OxyContin experience can teach us
The history of OxyContin illustrates why this deserves attention without proving that the same pattern will occur with 7-OH.
After OxyContin was reformulated in 2010, research found reduced misuse of the reformulated product, while some studies also identified substitution toward heroin and later illicit synthetic opioids. Other research did not find a significant increase in heroin initiation.
The lesson is not that restricting 7-OH will produce the same outcome. It is that people who are already dependent need access to treatment when the substance they rely on becomes harder to obtain.
Struggling to Stop 7-OH? Here’s When to Get Help
You do not need to wait for New Jersey restrictions to take effect. Consider a professional assessment if you use kratom or 7-OH regularly, need increasing amounts, experience withdrawal when you stop, hide your use, or feel unable to quit.
Concentrated 7-OH can cause physical dependence and withdrawal. If access changes, do not switch to another opioid or intoxicating substance to avoid withdrawal, as unknown potency and polysubstance use can create additional risks.
Conclusion
New Jersey’s proposed 7-OH restrictions may change availability of 7-OH products, but they do not eliminate dependence or withdrawal. If you are relying on kratom use or concentrated 7-OH every day, increasing your consumption, or struggling to stop, do not wait for your supply to run out or turn to another substance to manage withdrawal.
At Relevance Recovery, we provide addiction recovery and mental health treatment to help you address substance dependence with professional support. Start your recovery today rather than waiting for a regulatory change to become a personal crisis.
Frequently Asked Questions
Is 7-OH Already Illegal in New Jersey?
Not statewide, based on the current New Jersey legislative record. Senate Bill 301 proposes classifying 7-OH as a Schedule I controlled dangerous substance, and Assembly Bill 1636 proposes both Schedule I classification and a ban on products containing 7-OH. These are legislative proposals, not the same as an enacted statewide ban.
What Is Behind the Push to Ban 7-OH?
The primary concerns involve 7-OH’s potent activity at the mu-opioid receptor, the growth of concentrated and semisynthetic products, inconsistent labeling, potential for dependence and withdrawal, and increasing reports of harmful kratom-related exposures. The FDA has specifically focused its warnings and regulatory recommendations on concentrated 7-OH products.
Can 7-OH Cause Addiction?
Regular use of concentrated 7-OH can lead to physical dependence and may contribute to a substance use disorder. Clinical evidence has documented opioid-like withdrawal after abrupt discontinuation of high-dose 7-OH, while FDA reports also describe withdrawal and other adverse effects associated with 7-OH products.
How Does 7-OH Differ From Kratom?
Traditional kratom is plant material from Mitragyna speciosa containing multiple alkaloids, with 7-OH naturally present at trace levels. Many newer 7-OH products are concentrated or semisynthetic formulations designed to deliver substantially higher amounts of 7-OH. They should not automatically be treated as equivalent to traditional botanical kratom.
What Does 7-OH Withdrawal Feel Like?
Reported symptoms can include restlessness, anxiety, gastrointestinal symptoms such as nausea and diarrhea, abdominal discomfort, chills or clamminess, body aches, fatigue, irritability, cold sweats, and sleep problems. The severity and course can vary depending on factors such as dose, duration of use, and individual circumstances. A clinical case report has documented acute opioid withdrawal after stopping high-dose concentrated 7-OH.
Will New Jersey’s Ban Include Kratom?
It depends on which proposal and product are being discussed. Senate Bill 301 specifically addresses 7-OH, while Senate Bill 1384 proposes regulating kratom products rather than banning all kratom. The latter would restrict certain products based on 7-OH concentration and synthetic alkaloid content.
Where Can You Get Help for 7-OH Dependence?
If regular kratom or 7-OH use has become difficult to control, an addiction-treatment professional can evaluate your substance use, withdrawal concerns, and mental health needs and help identify appropriate support. Relevance Recovery provides addiction recovery and mental health treatment for people who are ready to address substance dependence.
